Prospective Validation of the OHI Index

A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index

Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) > 3,900 U/mL and ferritin >1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.

The investigators will enroll patients with new/transformed hematologic malignancies. The investigators will follow the patients until the end of the study, report their survival at one year and examine their prognosis.

Inclusion Criteria:

• Patients with hematologic malignancies
• At least 18 years old

Exclusion Criteria:

• Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)